Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Myriad Genetics Inc
(NQ:
MYGN
)
18.63
+0.03 (+0.16%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
481,133
Open
18.54
Bid (Size)
17.59 (1)
Ask (Size)
19.35 (1)
Prev. Close
18.60
Today's Range
18.37 - 18.84
52wk Range
13.82 - 24.21
Shares Outstanding
89,900,000
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
April 17, 2024
80% of people diagnosed with anxiety, depression report losing years or decades of time
From
Myriad Genetics, Inc.
Via
GlobeNewswire
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
April 16, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Performance
YTD
-1.95%
-1.95%
1 Month
-15.24%
-15.24%
3 Month
-13.59%
-13.59%
6 Month
+26.82%
+26.82%
1 Year
-12.82%
-12.82%
More News
Read More
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
April 09, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics: Q4 Earnings Insights
February 27, 2024
Via
Benzinga
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
March 21, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
March 20, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the
February 27, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Earnings Scheduled For February 27, 2024
February 27, 2024
Via
Benzinga
Myriad Genetics Earnings Preview
February 26, 2024
Via
Benzinga
Peeling Back The Layers: Exploring Myriad Genetics Through Analyst Insights
January 29, 2024
Via
Benzinga
Evaluating Myriad Genetics: Insights From 4 Financial Analysts
December 21, 2023
Via
Benzinga
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
February 27, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
February 21, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health
February 15, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
February 01, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
January 30, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
January 18, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO
January 09, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Genetic Testing Pioneer Myriad Genetics' Evolution Draws Analyst Attention Amid New Product(s) Anticipation
December 21, 2023
Via
Benzinga
Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance
December 21, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care
December 20, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents
November 20, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers
November 16, 2023
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Why AMC Entertainment Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
November 09, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.